In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low-quantity (FFPE or FNA) tumor biopsies. We will also discuss how these markers can be queried using a unified assay approach that reveals cancer-associated DNA and RNA variants from total nucleic acid. Finally, we will share lessons learned from building high-performance, multi-modal cancer panels that incorporate functional nucleic acid quantification, highly multiplexed target enrichment, and versatile and complementary variant call pipelines. These methods can enable reliable detection and quantification of DNA mutations, expression markers, and RNA fusions across multiple disease pathways and cancer types to advance diagnostic, theranostic and prognostic applications, and support retrospective studies, clinical trial assays, and in vitro diagnostic products.
Objectives of webinar: